Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature review-Reference-Cited by-同舟云学术

Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer’s disease: A literature review

Published:2019-11-07 Issue:2 Volume:57 Page:86-98
ISSN:1040-8363
Container-title:Critical Reviews in Clinical Laboratory Sciences
language:en
Short-container-title:Critical Reviews in Clinical Laboratory Sciences

Author:

Wesenhagen Kirsten E. J.¹,Teunissen Charlotte E.²,Visser Pieter Jelle¹,Tijms Betty M.¹

Affiliation:

1. Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands;

2. Neurochemistry Lab and Biobank, Department of Clinical Chemistry, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands

Publisher

Informa UK Limited

Subject

Biochemistry, medical,Clinical Biochemistry,General Biochemistry, Genetics and Molecular Biology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10408363.2019.1670613

Reference71 articles.

1. 2017 Alzheimer's disease facts and figures

2. Global action plan on the public health response to dementia 2017 - 2025 [Internet]. Geneva (Switzerland): WHO, World Health Organization; 2017.

3. Alzheimer’s Disease International. Policy Brief: The Global Impact of Dementia 2013–2050; Policy Brief: The Global Impact of Dementia 2013–2050 [Internet].

4. Alzheimer Europe. 2019. Work Plan – Our work – Alzheimer Europe – Alzheimer Europe [Internet]. [cited 2019 Apr 4]. Available from: https://www.alzheimer-europe.org/Alzheimer-Europe/Our-work/2019-Work-Plan

5. On the path to 2025: understanding the Alzheimer’s disease continuum

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mediation Analysis with Multiple Exposures and Multiple Mediators;Statistics in Medicine;2024-09-09

2. Alzheimer's disease genetic pathways impact cerebrospinal fluid biomarkers and imaging endophenotypes in non‐demented individuals;Alzheimer's & Dementia;2024-07-29

3. Alzheimer’s disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression;2024-06-13

4. Pathophysiological subtypes of mild cognitive impairment due to Alzheimer’s disease identified by CSF proteomics;Translational Neurodegeneration;2024-04-09

5. Micromotor-based electrochemical immunoassays for reliable determination of amyloid-β (1–42) in Alzheimer's diagnosed clinical samples.;Biosensors and Bioelectronics;2024-04